Semaglutide vs tirzepatide: the difference explained simply

Research context (RUO): Semaglutide and tirzepatide are incretin receptor agonists studied in research on metabolism and weight. Both are supplied at Peplife exclusively for in-vitro laboratory research and are not intended for human or animal use.

Semaglutide vs tirzepatide: the difference explained simply

Semaglutide and tirzepatide are often mentioned in the same breath, but they are not the same. The difference lies in one simple idea: how many “buttons” they press at the same time. Semaglutide presses one hormone receptor, tirzepatide two. That difference explains why they show divergent results in studies. This guide explains it in plain language.

What are incretins? — the switches briefly explained

Incretins are gut hormones released after a meal that regulate metabolism. Two are important here: GLP-1 (associated with satiety and slower gastric emptying) and GIP (which co-regulates the insulin response). An “agonist” is a molecule that activates such a receptor — presses the button. The distinction between semaglutide and tirzepatide is simply which buttons they press.

Semaglutide — the mono-agonist (GLP-1 only)

Semaglutide activates only the GLP-1 receptor. For years it was the benchmark in this research field. In the large phase 3 study STEP 1 (2021), researchers reported at the highest dose over 68 weeks an average weight reduction of about 14.9% compared with placebo. More detail can be found in the pillar semaglutide research.

Tirzepatide — the dual agonist (GIP and GLP-1)

Tirzepatide adds a second button: it activates both the GIP and the GLP-1 receptor. In research these two routes reinforce each other. In the phase 3 study SURMOUNT-1 (2022), researchers reported at the highest dose over 72 weeks an average weight reduction of up to about 20.9–22.5%. In the direct comparison study SURMOUNT-5 (2025), tirzepatide moreover showed a greater effect than semaglutide. More in tirzepatide research.

Semaglutide vs tirzepatide: the essentials at a glance

• Receptors: semaglutide = only GLP-1 (mono); tirzepatide = GIP + GLP-1 (dual).
• Reported weight loss: semaglutide about 14.9% (STEP 1); tirzepatide about 20.9–22.5% (SURMOUNT-1).
• Direct comparison: in SURMOUNT-5, tirzepatide showed a greater effect than semaglutide.
• Caveat: the studies differ in design and population, so the figures are indicative.

If you want to see the whole family in context — including the triple agonist retatrutide and the dual glucagon/GLP-1 agonist survodutide — take a look at the overview hub comparing GLP-1 peptides and the broader comparison Retatrutide vs tirzepatide vs semaglutide.

In the lab: handling & dissolving

Both are supplied as freeze-dried powder that is reconstituted with a suitable liquid before use. See reconstitute peptides.

Quality & purity

Every relevant batch is independently HPLC-tested by an external laboratory; the CoA is publicly verifiable per batch. See also why we rejected a batch.

SURMOUNT-5: the head-to-head comparison

For a long time we had to make do with separate studies in which each substance was tested against placebo on its own. SURMOUNT-5 put them side by side for the first time: 751 participants, 32 study sites, 72 weeks, tirzepatide at the maximum tolerated dose of 10 or 15 mg versus semaglutide at 1.7 or 2.4 mg. Both weekly and subcutaneous.

The gap of just over six percentage points is the clearest signal so far in the research field that adding GIP does more than simply amplify the GLP-1 effect. That said: this is one study, in one population, with these two dosing schedules. Other populations and other endpoints may give a different picture.

Pharmacokinetics and dosing schedule side by side

Both peptides are designed for one administration per week, but the underlying kinetics differ. Semaglutide has a half-life of about seven days, tirzepatide about five days. Both only reach a steady plasma level after four to five weeks, which explains why study protocols use titration steps of four weeks. Semaglutide also exists in an oral form; tirzepatide so far only as an injection.

Why GIP makes the difference

GLP-1 and GIP are both incretins, but they act at different points. GLP-1 works strongly on gastric emptying and on the satiety centres in the brainstem. GIP additionally has a direct role in adipose tissue: it influences how fat cells store and release energy, and in research it appears to partly dampen the nausea that goes with GLP-1 activation. That dampening effect is one of the explanations why studies with tirzepatide often see higher doses tolerated than with a pure GLP-1 agonist.

Retatrutide goes a step further, addressing the glucagon receptor alongside GLP-1 and GIP. See retatrutide research for the phase 2 figures, or amylin versus incretin for the fourth route.

Frequently asked questions

What is the main difference between semaglutide and tirzepatide?
Semaglutide activates only the GLP-1 receptor; tirzepatide activates both GIP and GLP-1. That extra receptor is associated in studies with a greater effect on body weight.

Which showed more weight loss in research?
Tirzepatide, at about 20.9–22.5% (SURMOUNT-1) versus about 14.9% for semaglutide (STEP 1), and a greater effect in the direct comparison SURMOUNT-5. The studies differ in design, so the figures are indicative.

Are they interchangeable in research?
No. They differ in receptor profile and potency and are treated as separate molecules with their own reference data.

How do they compare to retatrutide?
Retatrutide adds a third receptor (glucagon). See the comparison retatrutide vs tirzepatide vs semaglutide.

May I use these peptides to lose weight?
No. Both are intended exclusively for in-vitro laboratory research (RUO), not for humans or animals.

Read more & research at Peplife

• Research Semaglutide · Research Tirzepatide
• Semaglutide research · Tirzepatide research
• Compare GLP-1 peptides (hub)
• Retatrutide vs tirzepatide vs semaglutide
• All metabolism peptides

Sources: Wilding et al., STEP 1, NEJM 2021 · Jastreboff et al., SURMOUNT-1, NEJM 2022 · Aronne et al., SURMOUNT-5, NEJM 2025

Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.